Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept in moderate and severe NPDR (PRAVA)
NCT04702048Phase 4Withdrawn
- Sponsor
- University of Rochester
- Start
- Feb 2021
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept, sponsored by University of Rochester. Planned start Feb 2021; status: withdrawn.
02
Drugs
aflibercept
Beyond the preview
Go deeper on NCT04702048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702048.